Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Polymorphic light eruption (PLE) is the most common form among UV-inducible disorders with a prevalence of approximately 11-21% worldwide and a clear predisposition of women. Usually, within several hours after an intense UV exposure, most likely in spring or early summer, the formation of itchy skin lesions particularly at the upper arms and V-neck and neck is distinctive for PLE. It has been suggested that the development of a potential photo-induced antigen may initiate a delayed-type hypersensitivity reaction in PLE (causing the skin rash) and the microbiota of the skin may be involved. We thus hypothesized that eliminating the microbiota of the skin by disinfection may affect the formation of PLE. The concept of this study covers a combined interindividual and intraindividual half-body comparison of the skin reactions of disinfected and contralateral non-disinfected areas upon UV exposure in PLE patients and healthy subjects.
UV-induced erythema and pigmentation is quantified by visual scoring and reflectance spectroscopy to determine the minimum erythema dose (MED) exploring the fields of an UV test ladder on the dorsal skin of the study subjects.
Investigations after determining the MED and consecutive photo provocations on 4 subsequent days (PLE group only) using solar simulated UV radiation with slight dose increments include a half-body site comparison of test areas located on the back of the subjects in a randomized, double blinded manner. The microbiota of a respective test area is removed by the disinfection with Octeniderm (octenidine dihydrochloride, 1-propanol, 2- propanol) whereas a control site remains non-disinfected (sham-treated with physiologic sodium chloride solution).
The PLE related symptoms are evaluated by a validated PLE score, which is composed as follows:
Affected skin area (AA) [range, 0-4] + skin infiltration (SI) [range, 0-4] + 0.4 pruritus (P) [range, 0-10]; ([total range 0-12].
As additional procedures, tape strips and skin swabs are taken immediately after UV exposures. The material is used for shotgun metagenomic sequencing of microbes and further analysis such as quantitative measures of antimicrobial peptides and urocanic acid levels. Furthermore, suction blisters are produced after MED testing and the last day of photo provocation [Time Frame: At day 3 and 6] to profile the inflammatory milieu of the skin by transcriptomics. The epidermal blister roof is used together with optional skin biopsies (PLE patients only) for various investigations, including H/E and immunohistochemical stainings and messenger ribonucleic acid (mRNA) analysis.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Polymorphic light eruption patients | Experimental | PLE patients subjected to MED testing and photoprovocation |
|
| Healthy subjects | Other | Normal healthy subjects |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Octeniderm (octenidine dihydrochloride, 1-propanol, 2- propanol) | Other | Administering Octeniderm (octenidine dihydrochloride, 1-propanol, 2- propanol) or 0,9% sodium chloride (as control agent) to the skin |
| Measure | Description | Time Frame |
|---|---|---|
| Quantification of PLE | determined by PLE score (range, 0-12) of photo provocation results (0 best, 12 worst) | 1 week |
| Quantification of erythema score (range, 0-4) | determined by visual and spectroscopic erythema score | 1 week |
| Quantification of pigmentation (range, 0-4) | determined by visual and spectroscopic erythema score | 1 week |
| Measure | Description | Time Frame |
|---|---|---|
| Measurement of multiple cytokines (panel of 96 cytokines) | determined by transcriptomics | 1 week |
| Assessment of multiple microbiomes of the skin (quantity and variety) | determined by metagenomics |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Peter Wolf, MD | Contact | 0043 316 385 | 80315 | peter.wolf@medunigraz.at |
| Maximilian Zarfl | Contact | 00 43 660 6682953 | maximilian.zarfl@stud.medunigraz.at |
| Name | Affiliation | Role |
|---|---|---|
| Peter Wolf, MD | Medical University of Graz | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Dermatology, Medical University of Graz | Recruiting | Graz | Styria | 8036 | Austria |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| C034213 | octenidine |
| D000433 | 1-Propanol |
| D019840 | 2-Propanol |
| ID | Term |
|---|---|
| D020005 | Propanols |
| D000438 | Alcohols |
| D009930 | Organic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 1 week |
| Measurement of quantity and quality of multiple Antimicrobial peptides (AMP) | determined by proteomics | 1 week |
| Measurement of concentration of cis/trans-urocanic acid | determined by high pressure liquid chromotography (HPLC) | 1 week |
| Quantification of cellular skin infiltration (T cells, granulocytes and macrophages) | determined by hematoxylin and eosin (H/E) and immunohistochemical stainings | 1 week |